keyword
MENU ▼
Read by QxMD icon Read
search

ovarian cancer cytoreduction

keyword
https://www.readbyqxmd.com/read/28527673/minimal-access-surgery-compared-to-laparotomy-for-secondary-surgical-cytoreduction-in-patients-with-recurrent-ovarian-carcinoma-perioperative-and-oncologic-outcomes
#1
Ane Gerda Z Eriksson, Ashley Graul, Miao C Yu, Anthony Halko, Dennis S Chi, Oliver Zivanovic, Ginger J Gardner, Yukio Sonoda, Richard R Barakat, Nadeem R Abu-Rustum, Mario M Leitao
OBJECTIVES: To assess the perioperative outcomes of minimal access surgery (MAS) in secondary surgical cytoreduction (SSCR) for recurrent epithelial ovarian cancer (ROC); to compare oncologic outcomes with laparotomy (LAP). METHODS: Using an institutional database, we identified all patients with ROC undergoing SSCR from 1/5/09-6/14/14. Selection for MAS or LAP was based on surgeon preference. To minimize selection bias, preoperative imaging was reviewed for all LAP cases...
May 17, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28512408/cytoreductive-surgery-followed-by-hyperthermic-intraperitoneal-chemotherapy-for-recurrent-ovarian-cancer-with-incidental-bochdalek-hernia-and-postoperative-bilateral-thalamic-infarct-a-case-report
#2
Ilker Kahramanoglu, Hasan Turan, Ece Yamak Altinpulluk, Zahid Mammadov, Tugan Bese, Macit Arvas, Fuat Demirkiran
Congenital Bochdalek hernia is a defect of the diaphragm and very rare in adults. Only around 100 cases have been reported in the literature. Herein, we present a case with a recurrent ovarian cancer who underwent secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. An oval defect with dimensions of 3 × 4 cm was seen in the left posterolateral site of the diaphragm during surgical exploration. In addition, a 6 × 3 cm iatrogenic right-sided diaphragmatic defect was found and repaired...
January 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/28506948/stage-iiic-transitional-cell-carcinoma-and-serous-carcinoma-of-the-ovary-have-similar-outcomes-when-treated-with-platinum-based-chemotherapy
#3
Gökhan Boyraz, Derman Başaran, Mehmet Coşkun Salman, Nejat Özgül, Kunter Yüce
OBJECTIVE: Previous studies reported better outcomes for transitional cell carcinoma (TCC) of the ovary when compared with more common histologic types such as serous epithelial ovarian cancers (EOCs). The aim of this study was to compare the survival outcomes of platinum- based chemotherapy in patients with stage IIIC TCCs and serous EOCs. MATERIAL AND METHODS: Clinicopathologic features and survival data of patients with FIGO stage IIIC TCC and serous EOC who had undergone primary surgery followed by six cycles of intravenous platinum/taxane between 2007 and 2015 were retrieved from the database of Hacettepe University Hospital...
March 15, 2017: Journal of the Turkish German Gynecological Association
https://www.readbyqxmd.com/read/28504691/cxcr3-mediates-ascites-directed-tumor-cell-migration-and-predicts-poor-outcome-in-ovarian-cancer-patients
#4
C Windmüller, D Zech, S Avril, M Boxberg, T Dawidek, B Schmalfeldt, M Schmitt, M Kiechle, H Bronger
Intraabdominal tumor dissemination is a major hallmark of epithelial ovarian cancer (EOC), but the underlying mechanisms have not been fully elucidated. The CXCR3 chemokine receptor supports migration of tumor cells to metastatic sites, but its role in ovarian cancer metastasis is largely unknown. Herein, we first screened two independent cohorts of high-grade serous ovarian cancers (HGSCs, discovery set n=60, validation set n=117) and 102 metastatic lesions for CXCR3 expression. In primary tumors, CXCR3 was particularly overexpressed by tumor cells at the invasive front...
May 15, 2017: Oncogenesis
https://www.readbyqxmd.com/read/28498236/feasibility-of-transabdominal-cardiophrenic-lymphnode-dissection-in-advanced-ovarian-cancer-initial-experience-at-a-tertiary-center
#5
Annalisa Garbi, Vanna Zanagnolo, Nicoletta Colombo, Giovanni Aletti, Maria Teresa Achilarre, Luca Bocciolone, Fabio Landoni, Stefania Rizzo, Roberto Biffi, Angelo Maggioni
OBJECTIVES: The purpose of this retrospective report is to define the safety and feasibility, based on our preliminary experience, of surgical transdiaphragmatic resection of enlarged cardiophrenic lymph nodes (CPLNs), as a part of upfront debulking surgery. Supradiaphragmatic nodes located between the diaphragm and the heart are frequently a location for lymph node metastasis in advanced ovarian cancer, and their removal is aimed to obtain no gross residual disease at the primary cytoreductive surgery often requiring aggressive surgical procedures...
May 12, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28476108/diaphragmatic-surgery-and-related-complications-in-primary-cytoreduction-for-advanced-ovarian-tubal-and-peritoneal-carcinoma
#6
Shuang Ye, Tiancong He, Shanhui Liang, Xiaojun Chen, Xiaohua Wu, Huijuan Yang, Libing Xiang
BACKGROUND: To evaluate the procedures and complications of diaphragm peritonectomy (DP) and diaphragm full-thickness resection (DFTR) during primary cytoreduction for advanced stage epithelial ovarian cancer. METHODS: All the patients with epithelial ovarian carcinoma who underwent diaphragm procedures at our institution between January 2009 and August 2015 were identified. Clinicopathological data were retrospectively collected from the patients' medical records...
May 5, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28468520/the-role-of-biomarkers-in-the-management-of-epithelial-ovarian-cancer
#7
Wei-Lei Yang, Zhen Lu, Robert C Bast
Despite advances in surgery and chemotherapy for ovarian cancer, 70% of women still succumb to the disease. Biomarkers have contributed to the management of ovarian cancer by monitoring response to treatment, detecting recurrence, distinguishing benign from malignant pelvic masses and attempting to detect disease at an earlier stage. Areas covered: This review focuses on recent advances in biomarkers and imaging for management of ovarian cancer with particular emphasis on early detection. Relevant literature has been reviewed and analyzed...
May 15, 2017: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/28456378/high-glucocorticoid-receptor-expression-predicts-short-progression-free-survival-in-ovarian-cancer
#8
Jennifer Taylor Veneris, Kathleen M Darcy, Paulette Mhawech-Fauceglia, Chunqiao Tian, Ernst Lengyel, Ricardo R Lastra, Tanja Pejovic, Suzanne D Conzen, Gini F Fleming
OBJECTIVE: To investigate the association of tumor glucocorticoid receptor (GR) expression and patient outcome in ovarian cancer. METHODS: GR expression was evaluated by immunohistochemistry using tissue microarrays of specimens from 481 patients with ovarian cancer and 4 patients with benign conditions. Low GR expression was defined as an intensity of 0 or 1+ and high GR as 2+ or 3+ in >1% of tumor cells. Analyses were performed to evaluate the relationship of GR expression with clinical characteristics, progression-free survival (PFS) and overall survival (OS)...
April 26, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28443762/prediction-of-therapy-response-in-ovarian-cancer-where-are-we-now
#9
Khalid El Bairi, Mariam Amrani, Abdul Hafeez Kandhro, Said Afqir
Therapy resistance is a major challenge in the management of ovarian cancer (OC). Advances in detection and new technology validation have led to the emergence of biomarkers that can predict responses to available therapies. It is important to identify predictive biomarkers to select resistant and sensitive patients in order to reduce important toxicities, to reduce costs and to increase survival. The discovery of predictive and prognostic biomarkers for monitoring therapy is a developing field and provides promising perspectives in the era of personalized medicine...
April 26, 2017: Critical Reviews in Clinical Laboratory Sciences
https://www.readbyqxmd.com/read/28438874/partial-cystectomy-for-atypical-isolated-recurrence-of-ovarian-adenocarcinoma-a-case-report-and-literature-review
#10
Nicolae Bacalbasa, Irina Balescu
BACKGROUND: Most cases with advanced-stage epithelial ovarian malignancies will experience recurrent disease at a certain moment of their evolution, even if maximal cytoreductive surgery has been performed at the moment of initial diagnosis. However, it seems that the best therapeutic strategy, in case of relapse, remains aggressive re-resection, with complete cytoreduction being the most efficient way to improve survival. MATERIALS AND METHODS: We present the case of a 55-year-old patient diagnosed with an isolated pelvic recurrence after stage IIIC surgically-treated ovarian cancer three years after primary cytoreduction...
May 2017: In Vivo
https://www.readbyqxmd.com/read/28438473/bevacizumab-and-paclitaxel-carboplatin-chemotherapy-and-secondary-cytoreduction-in-recurrent-platinum-sensitive-ovarian-cancer-nrg-oncology-gynecologic-oncology-group-study-gog-0213-a-multicentre-open-label-randomised-phase-3-trial
#11
Robert L Coleman, Mark F Brady, Thomas J Herzog, Paul Sabbatini, Deborah K Armstrong, Joan L Walker, Byoung-Gie Kim, Keiichi Fujiwara, Krishnansu S Tewari, David M O'Malley, Susan A Davidson, Stephen C Rubin, Paul DiSilvestro, Karen Basen-Engquist, Helen Huang, John K Chan, Nick M Spirtos, Raheela Ashfaq, Robert S Mannel
BACKGROUND: Platinum-based chemotherapy doublets are a standard of care for women with ovarian cancer recurring 6 months after completion of initial therapy. In this study, we aimed to explore the roles of secondary surgical cytoreduction and bevacizumab in this population, and report the results of the bevacizumab component here. METHODS: The multicentre, open-label, randomised phase 3 GOG-0213 trial was done in 67 predominantly academic centres in the USA (65 centres), Japan (one centre), and South Korea (one centre)...
April 21, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28430350/1st-evidence-based-italian-consensus-conference-on-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-for-peritoneal-carcinosis-from-ovarian-cancer
#12
Davide Cavaliere, Roberto Cirocchi, Federico Coccolini, Anna Fagotti, Massimiliano Fambrini, Orietta Federici, Domenica Lorusso, Marco Vaira, Marco Ceresoli, Paolo Delrio, Alfredo Garofalo, Sandro Pignata, Paolo Scollo, Vito Trojano, Andrea Amadori, Luca Ansaloni, Giuseppe Cariti, Franco De Cian, Pierandrea De Iaco, Michele De Simone, Marcello Deraco, Annibale Donini, Giammaria Fiorentini, Luigi Frigerio, Stefano Greggi, Antonio Macrì, Enrico Maria Pasqual, Franco Roviello, Paolo Sammartino, Cinzia Sassaroli, Giovanni Scambia, Carlo Staudacher, Patrizia Vici, Enrico Vizza, Mario Valle
Ovarian cancer (OC) remains relatively rare, although it is among the top 4 causes of cancer death for women younger than 50. The aggressive nature of the disease and its often late diagnosis with peritoneal involvement have an impact on prognosis. The current scientific literature presents ambiguous or uncertain indications for management of peritoneal carcinosis (PC) from OC, both owing to the lack of sufficient scientific data and their heterogeneity or lack of consistency. Therefore, the Italian Society of Surgical Oncology (SICO), the Italian Society of Obstetrics and Gynaecology, the Italian Association of Hospital Obstetricians and Gynaecologists, and the Italian Association of Medical Oncology conducted a multidisciplinary consensus conference (CC) on management of advanced OC presenting with PC during the SICO annual meeting in Naples, Italy, on September 10-11, 2015...
April 20, 2017: Tumori
https://www.readbyqxmd.com/read/28406844/the-role-of-he4-a-novel-biomarker-in-predicting-optimal-cytoreduction-after-neoadjuvant-chemotherapy-in-advanced-ovarian-cancer
#13
Francesco Plotti, Giuseppe Scaletta, Stella Capriglione, Roberto Montera, Daniela Luvero, Salvatore Lopez, Alessandra Gatti, Carlo De Cicco Nardone, Corrado Terranova, Roberto Angioli
OBJECTIVES: This study aimed to evaluate serum human epididymis protein 4 (HE4) changes during neoadjuvant chemotherapy (NACT) to establish HE4 predebulking surgery cutoff values and to demonstrate that CA125, HE4, and computed tomography (CT) taken together are better able to predict complete cytoreduction after NACT in advanced ovarian cancer patients. METHODS: From January 2006 to November 2015, patients affected by epithelial advanced ovarian cancer (International Federation of Gynecology and Obstetrics stage III-IV), considered not optimally resectable, were included in this prospective study...
May 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28389144/clear-cell-carcinomas-of-the-ovary-have-poorer-outcomes-compared-with-serous-carcinomas-results-from-a-single-center-taiwanese-study
#14
Fei-Chun Ku, Ren-Chin Wu, Lan-Yan Yang, Yun-Hsin Tang, Wei-Yang Chang, Jung-Erh Yang, Chun-Chieh Wang, Shih-Ming Jung, Cheng-Tao Lin, Ting-Chang Chang, Angel Chao, Chyong-Huey Lai
BACKGROUND/PURPOSE: To compare the clinical outcomes of Taiwanese patients with ovarian clear cell carcinomas (CCCs) and serous carcinomas (SCs). METHODS: We retrieved the clinical records of women with epithelial ovarian cancer (Stage I-IV) who received primary surgeries between 2000 and 2013. Cancer-specific survival (CSS), progression-free survival, and survival after recurrence (SAR) of CCC and SC patients were retrospectively compared. Multivariate analysis was used to identify the independent predictors of survival...
April 4, 2017: Journal of the Formosan Medical Association, Taiwan Yi Zhi
https://www.readbyqxmd.com/read/28373041/-intraperitoneal-photodynamic-therapy-for-peritoneal-metastasis-of-epithelial-ovarian-cancer-limits-and-future-prospects
#15
H Azaïs, S Mordon, P Collinet
High peritoneal recurrence rate in advanced epithelial ovarian cancer after complete macroscopic cytoreductive surgery and platinum-based chemotherapy, raises the issue of peritoneal microscopic disease management and requires the development of additional locoregional treatment strategies. Photodynamic therapy is an effective treatment already applied in other medical and surgical indications. After administration of a photosensitizer which accumulates in cancer cells, illumination with a light of adequate wavelength may induce photochemical reaction between photosensitizer and tissue oxygen which lead to reactive oxygen species production and cytotoxic phenomenon...
March 31, 2017: Gynecologie, Obstetrique, Fertilite & Senologie
https://www.readbyqxmd.com/read/28366546/trends-and-factors-associated-with-radical-cytoreductive-surgery-in-the-united-states-a-case-for-centralized-care
#16
A K Sinno, X Li, R E Thompson, E J Tanner, K L Levinson, R L Stone, S M Temkin, A N Fader, D S Chi, K Long Roche
OBJECTIVES: To describe the US national trends and factors associated with cytoreductive surgical radicality in women with advanced ovarian cancer (OC). METHODS: An analysis of the National Inpatient Sample database was performed. All admissions from 1993 to 2011 for advanced OC cytoreductive surgery (CRS) were identified and categorized as simple pelvic (SP), extensive pelvic (EP), and extensive upper abdominal (EUA) surgery. Annual trends in CRS were analyzed...
March 30, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28365932/usefulness-of-human-epididymis-protein-4-in-predicting-optimal-cytoreductive-therapy-in-patients-with-advanced-ovarian-cancer
#17
Vesna Paunovic, Zoran Protrka, Daniela Ardalic, Tomislav Paunovic
PURPOSE: Human Epididymis Protein 4 (HE4) is a novel promising serum biomarker of high sensitivity and specificity for ovarian cancer (OC). We investigated the usefulness of HE4 in predicting the outcome of surgery of advanced OC. METHODS: Fifty patients with OC (FIGO stage III and IV) entered the study. Serum concentrations of HE4 and CA125 were evaluated preoperatively. All patients had been operated between January 2014 - January 2016. RESULTS: Preoperatively, the mean concentration of HE4 was 628pmol/L...
January 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/28359805/-specific-folic-acid-targeted-photosensitizer-the-first-step-toward-intraperitoneal-photodynamic-therapy-for-epithelial-ovarian-cancer
#18
H Azaïs, C Frochot, A Grabarz, S Khodja Bach, L Colombeau, N Delhem, S Mordon, P Collinet
OBJECTIVE: Epithelial ovarian cancer (EOC) management remains association of debulking surgery in combination with platinum-based chemotherapy. Sixty percent of women with EOC considered in remission will develop recurrent disease. An option to improve the completion of cytoreductive surgery may be the use of photodynamic therapy to induce necrosis of peritoneal metastases. A limit of this technique was the toxicity induced by the lack of specificity of old-generation photosensitizer (PS) for tumor tissue if the light could not be specifically applied...
March 27, 2017: Gynecologie, Obstetrique, Fertilite & Senologie
https://www.readbyqxmd.com/read/28317584/dealing-with-microscopic-peritoneal-metastases-of-epithelial-ovarian-cancer-a-surgical-challenge
#19
REVIEW
Henri Azaïs, Juan Pablo Estevez, Périne Foucher, Yohan Kerbage, Serge Mordon, Pierre Collinet
Understanding biology and progression mechanisms of peritoneal metastases of epithelial ovarian cancer (EOC) is a cornerstone in the knowledge and the comprehensive management of the disease. Despite clinical remission after the association of complete cytoreductive surgery and platinum-based chemotherapy, peritoneal recurrence still occurs in 60% of patients. Eligible studies, published from 1980 to June 2016, were retrieved through ClinicalTrials.gov, MEDLINE, Cochrane databases and bibliography searches...
March 2017: Surgical Oncology
https://www.readbyqxmd.com/read/28317007/the-role-of-neoadjuvant-chemotherapy-in-the-management-of-patients-with-advanced-stage-ovarian-cancer-survey-results-from-members-of-the-society-of-gynecologic-oncologists-a-5-year-follow-up
#20
Erica Huelsmann, Israel Zighelboim, Amina Ahmed, Summer Dewdney
•NACT use among SGO members for ovarian cancer is explored given recent trials.•Fewer SGO members feel they can't predict optimal cytoreduction pre-operatively.•Laparoscopy use has increased both for diagnosis and treatment of ovarian cancer.•Very high optimal cytoreduction rates are reported from SGO members.•Despite recent studies, SGO members don't regularly treat patients with NACT/ID.
May 2017: Gynecologic Oncology Reports
keyword
keyword
111476
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"